Carbohydrate-Recognition and Angiogenesis

Jackson RL, Busch SJ, Cardin AD: Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71: 481-539, 1991 Baird A, Klagsbrun M: The fibroblast growth factor family. Cancer Cells 3: 239-243, 1991 Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK: Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 149: 59-71, 1996 Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58: 575-606, 1989 Gospodarowicz D: Biological activities of fibroblast growth factors. Ann NY Acad Sci 638: 1-8, 1991 Folkman J, Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987 Wang Y, Becker D: Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 3: 887-893, 1997 Konerding MA, Fait F, Dimitropoulou C, Malkusch W, Fern C, Giavazzi R, Coltrini D, Presta M: Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. Am J Pathol 152: 1607-1616, 1998 Vlodavsky I, Folkman J, Sullivan R, Fridman R. Ishai-Michaeli R, Sasse J, Klagsbrun M: Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84: 2292-2296, 1987 Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I: A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 130: 393-400, 1988 Pantoliano MW, Horlick RA, Springer BA, Van Dyk DE, Tobery T, Wetmore DR, Lear JD, Nahapetian AT, Bradley JD, Sisk WP: Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry 33: 10229-10248, 1994 Reiland J, Rapraeger AC: Heparan sulfate proteoglycan and FGF receptor target basic FGF to different intracellular destinations. J Cell Sci 105: 1085-1093, 1993 Roghani M, Moscatelli D: Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J Biol Chem 267: 22 156-22 162, 1992 Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL: An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259: 1918-1921, 1993 Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi F, Leder P: Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12: 240-247, 1992 Thompson LD, Pantoliano MW, Springer BA: Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33: 3831-3840, 1994 Li LY, Safran M, Aviezer D, Bohlen P, Seddon AP, Yayon A: Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry 33: 10999-11007, 1994 Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC: Heparin structure and interactions with basic fibroblast growth factor. Science 271: 1116-1120, 1996 Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn CM, Waksman G: FGF binding and FGF receptor activation by synthetic heparan-derived di-and trisaccharides. Science 268: 432-436, 1995 Moy FJ, Safran M, Seddon AP, Kitchen D, Bohlen P, Aviezer D, Yayon A, Powers R: Properly oriented heparindecasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor. Biochemistry 36: 4782-4791, 1997 Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993 Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393-401, 1996 Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominantnegative Flk-1 mutant. Nature 367: 576-579, 1994 Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M: Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55: 1189-1193, 1995 Dvorak AM, Kohn S, Morgan ES, Fox P, Nagy JA, Dvorak HF: The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol 59: 100-115, 1996 Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W: Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140: 947-959, 1998 Roberts WG, Palade GE: Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57: 765-772, 1997 Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, Dvorak AM, van de Water L, Sioussat TM, Senger DR: Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann NY Acad Sci 667: 101-111, 1992 Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 359: 843-845, 1992 Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992 Tischer F, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991 Park JE, Keller GA, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317-1326, 1993 Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi BZ, Neufeld G: VFGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VFGF receptors of human melanoma cells. J Biol Chem 270: 11322-11326, 1995 Cheng SY, Nagane M, Huang HS, Cavenee WK: Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 94: 12081-12087, 1997 Jonca F, Ortega N, Gleizes PE, Bertrand N, Plouet J: Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J Biol Chem 272: 24203-24209, 1997 Gengrinovitch S, Berman B, David G, Witte L, Neufeld G, Ron D: Glypican-1 is a VFGF165 binding proteoglycan that acts as an extracellular chaperone for VFGF165. J Biol Chem 274: 10816-10822, 1999 Schlessinger J, Lax I, Lemmon M: Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 83: 357-360, 1995 West DC, Kumar S: The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res 183: 179-196, 1989 Johnson P, Maiti A, Brown KL, Li R: A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response? Biochem Pharmacol 59: 455-465, 2000 Stamenkovic I, Amiot M, Pesando JM, Seed B: A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56: 1057-1062, 1989 Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF, Butcher EC: A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 56: 1063-1072, 1989 Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A: Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 273: 338-343, 1998 Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A: Identi-fication of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 122: 257-264, 1993 Kohda D, Morton CJ, Parkar AA, Hatanaka H, Inagaki FM, Campbell ID, Day AJ: Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration. Cell 86: 767-775, 1996 Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301-314, 1994 Tedder TF, Steeber DA, Chen A, Engel P: The selectins: vascular adhesion molecules. Faseb J 9: 866-873, 1995 Lasky LA: Selectin-carbohydrate interactions and the initiation of the inflammatory response. Annu Rev Biochem 64: 113-139, 1995 Slevin M, Krupinski J, Kumar S, Gaffney J: Angiogenic oligosaccharides of hyaluronan induce protein tyrosine kinase activity in endothelial cells and activate a cytoplasmic signal transduction pathway resulting in proliferation. Lab Invest 78: 987-1003, 1998 Nguyen M, Folkman J, Bischoff J: 1-Deoxymannojirimycin inhibits capillary tube formation in vitro. Analysis of N-linked oligosaccharides in bovine capillary endothelial cells. J Biol Chem 267: 26157-26165, 1992 Nguyen M, Strubel NA, Bischoff J: A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365: 267-269, 1993 Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376: 517-519, 1995 Kraling BM, Razon MJ, Boon LM, Zurakowski D, Seachord C, Darveau RP, Mulliken JB, Corless CL, Bischoff J: E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 148: 1181-1191, 1996 Morbidelli L, Brogelli L, Granger HJ, Ziche M: Endothelial cell migration is induced by soluble P-selectin. Life Sci 62: L7-11, 1998 Varki A: Selectin ligands. Proc Natl Acad Sci USA 91: 7390-7397, 1994 Nguyen M, Eilber FR, Defrees S: Novel synthetic analogs of sialyl Lewis X can inhibit angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 228: 716-723, 1996 Gerritsen ME, Shen CP, Atkinson WJ, Padgett RC, Gimbrone Jr. MA, Milstone DS: Microvascular endothelial cells from E-selectin-deficient mice form tubes in vitro. Lab Invest 75: 175-184, 1996 Hartwell DW, Butterfield CE, Frenette PS, Kenyon BM, Hynes RO, Folkman J, Wagner DD: Angiogenesis in P-and E-selectin-deficient mice. Microcirculation 5: 173-178, 1998 Barondes SH, Cooper DN, Gitt MA, Leffler H: Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269: 20 807-20 810, 1994 Herrmann J, Turck CW, Atchison RE, Huflejt ME, Poulter L, Gitt MA, Burlingame AL, Barondes SH, Leffler H: Primary structure of the soluble lactose binding lectin L-29 from rat and dog and interaction of its non-collagenous proline-, glycine-, tyrosine-rich sequence with bacterial and tissue collagenase. J Biol Chem 268: 26 704-26 711, 1993 Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A: Galectin-3: a novel antiapoptotic molecule with a functional BHI (NWGR) domain of Bcl-2 family. Cancer Res 57: 5272-5276, 1997 Nangia-Makker P, Akahani S, Bresalier R, Raz A: The role of galectin-3 in metastasis. In: Seve A-P, Caron M (eds) Lectins and Pathology. Harwood Academic Publishers, 2000, pp 67-78 Perillo NL, Marcus ME, Baum LG: Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76: 402-412, 1998 Ochieng J, Green B, Evans S, James O, Warfield P: Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochim Biophys Acta 1379: 97-106, 1998 Inohara H, Raz A: Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 55: 3267-3271, 1995 Lotan R, Belloni PN, Tressler RJ, Lotan D, Xu XC, Nicolson GL: Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. Glycoconj J 11: 462-468, 1994 Gordower L, Decaestecker C, Kacem Y, Lemmers A, Gusman J, Burchert M, Danguy A, Gabius H, Salmon I, Kiss R, Camby I: Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Appl Neurobiol 25: 319-330, 1999 Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A: Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156: 899-909, 2000 Van den Brule F, Castronovo V: Limmin-binding lectins during cancer invation and metastasis. In: Caron M, Seve A-P (eds) Lectins and Pathology. Harwood Academic Publishers, 2000, pp 79-123 Newham P, Humphries MJ: Integrin adhesion receptors: structure, function and implications for biomedicine. Mol Med Today 2: 304-313, 1996 Sheppard D: Epithelial integrins. Bioessays 18: 655-660, 1996 Dejana E, Languino LR, Collella S, Corbascio GC, Plow E, Ginsberg M, Marchisio PC: The localization of a platelet GpIIb-IIIa-related protein in endothelial cell adhension structures. Blood 71: 566-572, 1998 Bischoff J: Cell adhension and angiogenesis. J Clin Invest 99: 373-376, 1997 Stromblad S, Cheresh DA: Integrins, angiogenesis and vascular cell survival. Chem Biol 3: 881-885, 1996 Horton MA: The alpha v beta 3 integrin “vitronectin receptor”. Int J Biochem Cell Biol 29: 721-725, 1997 Ruoslahti E, Pierschbacher MD: Arg-Gly-Asp: a versatile cell recognition signal. Cell 44: 517-518, 1986